Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dimebon (latrepirdine) | Experimental | Dimebon, 20 mg orally three times daily |
|
| Placebo | Placebo Comparator | Placebo orally three times daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dimebon (latrepirdine) | Drug | 20 mg orally three times daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Neuropsychiatric Inventory (NPI) | To evaluate the efficacy of dimebon (latrepirdine) as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI) | 26 weeks post baseline |
| Activities of Daily Living (severe) (ADCS ADLsev) | To evaluate the efficacy of dimebon as compared to placebo on a measure of self-care and daily function, the Alzheimer's Disease Cooperative Study - Activities of Daily Living (severe) (ADCS ADLsev). | 26 weeks post baseline |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Santiago | Chile | |||||
Not provided
| ID | Term |
|---|---|
| C010119 | latrepirdine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo orally three times daily |
|
| Glasgow |
| Scotland |
| United Kingdom |